Travere Therapeutics (TVTX) Non-Current Deferred Tax Liability (2013 - 2017)

Travere Therapeutics' Non-Current Deferred Tax Liability history runs 5 years deep, the most recent figure standing at $16.8 million for Q4 2017.

• Quarterly Non-Current Deferred Tax Liability fell 65.48% year-over-year to $16.8 million in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $16.8 million (down 65.48% YoY) and the FY2017 annual result came in at $16.8 million, down 65.48% from the prior year.
• Non-Current Deferred Tax Liability was $16.8 million for Q4 2017 at Travere Therapeutics, up from $1.2 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $48.7 million in Q4 2016 and bottomed at $141000.0 in Q4 2014.
• A 5-year average of $14.6 million and a median of $12.1 million in 2016 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2014 — Non-Current Deferred Tax Liability sank 94.58% — and 2015, when it jumped 17153.9%.
• Travere Therapeutics' Non-Current Deferred Tax Liability stood at $2.6 million in 2013, then sank by 94.58% to $141000.0 in 2014, then soared by 17153.9% to $24.3 million in 2015, then jumped by 100.18% to $48.7 million in 2016, then plunged by 65.48% to $16.8 million in 2017.
• Business Quant data shows TVTX's Non-Current Deferred Tax Liability at $16.8 million in Q4 2017, $1.2 million in Q2 2017, and $4.4 million in Q1 2017.